776.44
price up icon1.87%   14.26
pre-market  Pre-mercato:  778.30   1.86   +0.24%
loading
Precedente Chiudi:
$762.18
Aprire:
$763.34
Volume 24 ore:
2.44M
Relative Volume:
0.63
Capitalizzazione di mercato:
$735.86B
Reddito:
$49.00B
Utile/perdita netta:
$11.11B
Rapporto P/E:
63.18
EPS:
12.29
Flusso di cassa netto:
$-1.27B
1 W Prestazione:
+0.61%
1M Prestazione:
+1.80%
6M Prestazione:
+2.98%
1 anno Prestazione:
-10.34%
Intervallo 1D:
Value
$762.50
$778.29
Intervallo di 1 settimana:
Value
$760.02
$796.04
Portata 52W:
Value
$677.09
$972.53

Lilly Eli Co Stock (LLY) Company Profile

Name
Nome
Lilly Eli Co
Name
Telefono
(317) 276-2000
Name
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Dipendente
47,000
Name
Cinguettio
@LillyPad
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
LLY's Discussions on Twitter

Confronta LLY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
LLY
Lilly Eli Co
776.44 692.83B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
167.93 373.35B 90.63B 22.66B 18.57B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
187.11 329.24B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
116.83 231.66B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
66.78 298.68B 43.59B 15.04B 10.74B 3.3766

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-05 Downgrade Erste Group Buy → Hold
2025-04-28 Downgrade HSBC Securities Buy → Reduce
2025-04-22 Iniziato Cantor Fitzgerald Overweight
2024-12-10 Ripresa BofA Securities Buy
2024-11-15 Iniziato Wolfe Research Outperform
2024-10-17 Iniziato Bernstein Outperform
2024-09-13 Ripresa Citigroup Buy
2024-08-12 Aggiornamento Deutsche Bank Hold → Buy
2024-02-21 Downgrade DZ Bank Buy → Hold
2024-02-16 Reiterato Morgan Stanley Overweight
2023-12-21 Downgrade Daiwa Securities Buy → Outperform
2023-11-09 Iniziato Deutsche Bank Hold
2023-10-20 Ripresa UBS Buy
2023-08-09 Aggiornamento Jefferies Hold → Buy
2023-07-26 Reiterato Citigroup Buy
2023-07-14 Iniziato HSBC Securities Buy
2023-05-24 Reiterato BofA Securities Buy
2023-05-24 Reiterato UBS Buy
2023-03-13 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-03-06 Iniziato Jefferies Hold
2023-02-15 Downgrade Societe Generale Hold → Sell
2022-11-18 Iniziato Credit Suisse Outperform
2022-09-22 Aggiornamento UBS Neutral → Buy
2022-05-23 Iniziato SVB Leerink Outperform
2022-04-06 Ripresa Morgan Stanley Overweight
2022-03-10 Iniziato Daiwa Securities Outperform
2022-01-21 Aggiornamento DZ Bank Hold → Buy
2022-01-03 Reiterato Bernstein Mkt Perform
2021-12-17 Iniziato Goldman Neutral
2021-12-16 Reiterato BMO Capital Markets Outperform
2021-12-16 Reiterato BofA Securities Buy
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-11-19 Iniziato BMO Capital Markets Outperform
2021-10-11 Aggiornamento Berenberg Hold → Buy
2021-09-29 Aggiornamento Citigroup Neutral → Buy
2021-08-05 Aggiornamento DZ Bank Hold → Buy
2021-07-27 Ripresa Truist Buy
2021-06-24 Reiterato Cantor Fitzgerald Overweight
2021-01-19 Aggiornamento Mizuho Neutral → Buy
2020-12-10 Aggiornamento Wolfe Research Peer Perform → Outperform
2020-11-10 Ripresa Bernstein Mkt Perform
2020-09-29 Iniziato Berenberg Hold
2020-09-03 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2020-06-16 Aggiornamento Guggenheim Neutral → Buy
2020-04-21 Downgrade UBS Buy → Neutral
2020-04-09 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-02-06 Iniziato Mizuho Neutral
2019-12-18 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2019-10-17 Ripresa BofA/Merrill Buy
2019-05-28 Iniziato Goldman Buy
2019-04-24 Aggiornamento Edward Jones Hold → Buy
2019-04-11 Downgrade Guggenheim Buy → Neutral
2019-03-12 Iniziato JP Morgan Overweight
2019-01-23 Iniziato UBS Buy
2018-11-26 Downgrade Citigroup Buy → Neutral
2018-10-31 Aggiornamento Credit Suisse Underperform → Neutral
2018-10-09 Iniziato Guggenheim Buy
2018-10-01 Reiterato SunTrust Buy
2018-09-26 Ripresa JP Morgan Overweight
Mostra tutto

Lilly Eli Co Borsa (LLY) Ultime notizie

pulisher
01:10 AM

Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer’s disease - GlobeNewswire Inc.

01:10 AM
pulisher
Jul 22, 2025

BMO Capital Pounds the Table on Eli Lilly Stock (LLY) Ahead of Earnings - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

BMO Capital reiterates Eli Lilly stock rating with $900 price target By Investing.com - Investing.com South Africa

Jul 22, 2025
pulisher
Jul 22, 2025

Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term - Yahoo.co

Jul 22, 2025
pulisher
Jul 22, 2025

Better Growth Buy: Eli Lilly vs. Viking Therapeutics - The Motley Fool

Jul 22, 2025
pulisher
Jul 21, 2025

Eli Lilly (LLY) at a Crossroads: Assessing the Pullback, Earnings Catalysts, and Long-Term Growth in Diabetes, Obesity, and Alzheimer's - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo.co

Jul 21, 2025
pulisher
Jul 21, 2025

Eli Lilly’s Strategic Advantage in GLP-1RAs and Alzheimer’s Markets Fuels Buy Rating - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

Eli Lilly: Competition Melts Away (NYSE:LLY) - Seeking Alpha

Jul 21, 2025
pulisher
Jul 20, 2025

Eli Lilly and Company (NYSE:LLY) Shares Could Be 38% Below Their Intrinsic Value Estimate - 富途牛牛

Jul 20, 2025
pulisher
Jul 20, 2025

Bernstein Remains Bullish on Eli Lilly and Company (LLY) With an $1,100 PT - Insider Monkey

Jul 20, 2025
pulisher
Jul 19, 2025

Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease - drugdiscoverytrends.com

Jul 19, 2025
pulisher
Jul 18, 2025

Why Eli Lilly (LLY) is Emerging as a Dividend Growth Leader in Pharma for 2025 - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

J.P. Morgan Sees Strong Q2 for Eli Lilly, Maintains Overweight Rating - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly and Company - Lifespan Research Institute

Jul 18, 2025
pulisher
Jul 18, 2025

Is Eli Lilly Stock A Buy On A Fresh Bout Of Alzheimer's News? - Investor's Business Daily

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s Innovative Study on Bimagrumab and Tirzepatide: Market Implications - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s New Study on LY4050784: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s LUCENT 3 Study: A Promising Step for Ulcerative Colitis Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s KRAS Inhibitor Study: A Potential Game-Changer in Cancer Treatment? - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s Lepodisiran Study: A Step Forward in Liver Function Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s Weight Management Study: A Potential Game-Changer in Obesity Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s Promising Phase 1 Study on LY4101174: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s New Cancer Study: A Potential Game-Changer? - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly & Co: Analyst Bullish on Diabetes Segment and Oncology Franchise Amid Competitive Pressures. - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly & Co: Promising Growth Prospects and Strategic Positioning Amid Competitive Pressures - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly's stock drops 3.08% to $765.51 on July 17, down 21.29% from 52-week high. - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs? - The Motley Fool

Jul 18, 2025
pulisher
Jul 17, 2025

Abbott, Eli Lilly Lead Thursday’s Market Cap Stock Movers By Investing.com - Investing.com India

Jul 17, 2025
pulisher
Jul 17, 2025

Abbott, Eli Lilly Lead Thursday’s Market Cap Stock Movers - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today? - Yahoo Finance

Jul 17, 2025
pulisher
Jul 17, 2025

Senators reveal how much Lilly, Pfizer paid telehealth companies - statnews.com

Jul 17, 2025
pulisher
Jul 17, 2025

LLY Stock Quote Price and Forecast - CNN

Jul 17, 2025
pulisher
Jul 16, 2025

Eli Lilly Bets Big On Obesity And Diabetes Drugs - Finimize

Jul 16, 2025
pulisher
Jul 16, 2025

Jim Cramer on Eli Lilly: “How Can You Leave This One Right Here?” - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

ELI LILLY AND COMPANY (LLY) - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound - CNBC

Jul 16, 2025
pulisher
Jul 16, 2025

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - Benzinga

Jul 16, 2025
pulisher
Jul 16, 2025

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Stoke Therapeutics (STOK) - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Health Canada Expands Eli Lilly's Omvoh Indication to Crohn's, Approves Citrate-Free Formula - MarketScreener

Jul 16, 2025
pulisher
Jul 15, 2025

Verve Offers $416K Award To GC Amid Lilly Acquisition - Law360

Jul 15, 2025
pulisher
Jul 15, 2025

Eli Lilly’s Weight-Loss Drug Faces New Competition from China - TipRanks

Jul 15, 2025
pulisher
Jul 15, 2025

Eli Lilly Foundation provides $5.5 million grant for STEM education initiative at IPS - Fox 59

Jul 15, 2025
pulisher
Jul 15, 2025

The Zacks Analyst Blog Highlights Lilly, Netflix, GE Aerospace, Willis Lease and Flanigan's Enterprises - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Eli Lilly: Still Too Pricey To Buy (NYSE:LLY) - Seeking Alpha

Jul 15, 2025
pulisher
Jul 15, 2025

Eli Lilly (LLY) Secures FDA Label Update for Alzheimer’s Disease Treatment - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

Eli Lilly (LLY) Gains Health Canada Approval for Omvoh in Crohn's Disease Treatment - GuruFocus

Jul 15, 2025
pulisher
Jul 15, 2025

Eli Lilly’s Obesity Pill For The Masses Could Flip The $150 Billion Market on Its Head! - Smartkarma

Jul 15, 2025
pulisher
Jul 14, 2025

Top Research Reports for Eli Lilly, Netflix & GE Aerospace - Yahoo Finance

Jul 14, 2025
pulisher
Jul 14, 2025

Eli Lilly (LLY) Expects Results from Weight-Loss Pill Trial by Sept. 30 - TipRanks

Jul 14, 2025

Lilly Eli Co Azioni (LLY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general JNJ
$167.93
price up icon 2.17%
$187.11
price up icon 1.22%
drug_manufacturers_general NVS
$116.83
price up icon 2.36%
drug_manufacturers_general NVO
$66.78
price up icon 2.87%
drug_manufacturers_general MRK
$81.61
price up icon 2.90%
Capitalizzazione:     |  Volume (24 ore):